



## Precision Medicine for Retinal Disease

Guest Editors:

**Dr. Sara Touhami**

1. Department of  
Ophthalmology, Pitié Salpêtrière  
University Hospital, Sorbonne  
Université, 75013 Paris, France

2. Department of  
Ophthalmology, Hôpital  
Lariboisière, Assistance Publique-  
Hôpitaux de Paris, Université de  
Paris, 75010 Paris, France

**Dr. Alexandra Miere**

Department of Ophthalmology,  
Creteil Hospital, Paris Est  
University, Créteil, France

Deadline for manuscript  
submissions:

**closed (20 June 2023)**

### Message from the Guest Editors

Dear Colleagues, Retinal diseases, such as diabetic retinopathy and age-related macular degeneration, to name only the most common, can still cause profound and irreversible visual loss, leading to significant morbidity worldwide. In the abovementioned indications, intravitreal injections of anti-VEGFs, which have obtained regulatory authorizations for more than 10 years, have allowed for a drastic reduction in the rate of blindness and morbidity, but at the cost of frequent visits and treatments during their initial use. The current objective of treatments in retinal pathology is not only to ensure visual recovery but also to limit the therapeutic burden. New treatment protocols have therefore emerged in recent years, making it possible to propose a therapeutic regimen adapted to each retinal disease and to each patient. Nonvascular retinal pathologies have also seen the advent of new precision therapies, such as retinal dystrophies, for which gene therapy allows targeted therapies adapted to each mutation. The future of the management of retinal diseases, whether medical or surgical, has a bright future ahead of it, with the watchword of the personalization of treatment.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)